Patents by Inventor Lawrence Wennogle
Lawrence Wennogle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11958852Abstract: The present invention relates to use of particular substituted heterocycle fused gamma-carbolines as described herein, in free, pharmaceutically acceptable salt or prodrug form, and pharmaceutical composition comprising the same optionally in combination with one or more agents, for the prophylaxis or treatment of one or more disorders associated with dementia, particularly behavioral or mood disturbances (e.g., agitation/aggression), psychosis, depression and sleep disturbances among others in patients suffering from dementia.Type: GrantFiled: August 18, 2021Date of Patent: April 16, 2024Assignee: INTRA-CELLULAR THERAPIES, INC.Inventors: Sharon Mates, Robert Davis, Kimberly Vanover, Lawrence Wennogle
-
Patent number: 11839614Abstract: The disclosure provides methods, treatments and materials for enhancing the effect of an adenosine A2 receptor agonist in the treatment, mitigation or prophylaxis of a disease or condition characterized by inotropic and/or lusitropic dysfunction, and/or enhancing adenosine A2 receptor function in the treatment, mitigation or prophylaxis of a disease or condition characterized by impaired adenosine A2 receptor function, comprising administration of an effective amount of a PDE1 inhibitor to a patient in need thereof, for example a patient suffering from heart failure.Type: GrantFiled: January 31, 2019Date of Patent: December 12, 2023Assignee: INTRA-CELLULAR THERAPIES, INC.Inventors: David Kass, Toru Hashimoto, Lawrence Wennogle, Joseph Hendrick, Robert Davis
-
Patent number: 11124514Abstract: The present invention relates to use of particular substituted heterocycle fused gamma-carbolines as described herein, in free, pharmaceutically acceptable salt or prodrug form, and pharmaceutical composition comprising the same optionally in combination with one or more agents, for the prophylaxis or treatment of one or more disorders associated with dementia, particularly behavioral or mood disturbances (e.g., agitation/aggression), psychosis, depression and sleep disturbances among others in patients suffering from dementia.Type: GrantFiled: September 27, 2019Date of Patent: September 21, 2021Assignee: INTRA-CELLULAR THERAPIES, INC.Inventors: Sharon Mates, Robert Davis, Kimberly Vanover, Lawrence Wennogle
-
Patent number: 10183023Abstract: The subject matter generally relates to methods of treatment and/or prophylaxis of CNS diseases, disorders, and/or injuries. In one aspect, the subject matter relates to inhibitors of phosphodiesterase 1 (PDE1) as neuroprotective agents and/or neural regenerative agents. In a further aspect, the subject matter relates to individuals that are at risk for the development of CNS disease or disorder.Type: GrantFiled: January 13, 2017Date of Patent: January 22, 2019Assignee: INTRA-CELLULAR THERAPIES, INC.Inventor: Lawrence Wennogle
-
Patent number: 10150774Abstract: The subject matter generally relates to compounds and methods of treatment and/or prophylaxis of CNS diseases, disorders, and/or injuries. In one aspect, the subject matter relates to inhibitors of phosphodiesterase 1 (PDE1) as neuroprotective agents and/or neural regenerative agents. In a further aspect, the subject matter relates to individuals that are at risk for the development of CNS disease or disorder.Type: GrantFiled: September 17, 2015Date of Patent: December 11, 2018Assignee: INTRA-CELLULAR THERAPIES, INC.Inventors: Peng Li, Hailin Zheng, Jun Zhao, Lawrence Wennogle
-
Patent number: 9616061Abstract: Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals and pharmaceutical compositions comprising them for the treatment of one or more disorders involving the 5-HT2A, SERT and/or dopamine D2 pathways are disclosed. In addition, the compounds may be combined with other therapeutic agents for the treatment of one or more sleep disorders, depression, psychosis, dyskinesias, and/or Parkinson's disease or any combinations.Type: GrantFiled: October 16, 2015Date of Patent: April 11, 2017Assignee: INTRA-CELLULAR THERAPIES, INC.Inventors: Sharon Mates, Allen Fienberg, Lawrence Wennogle
-
Patent number: 9605041Abstract: The invention provides a previously uncharacterized protein (gamma secretase activating protein or gSAP) that activates ?-secretase to produce ?-amyloid protein (A?). Deposition of A? has been associated with Alzheimer's disease and other pathologies. The invention thus additionally provides, e.g., screening methods and novel research tools, inhibitors of this novel protein, and methods of diagnosis, treatment and control of Alzheimer's disease and other neurodegenerative conditions associated with deposition of A?.Type: GrantFiled: February 6, 2012Date of Patent: March 28, 2017Assignees: INTRA-CELLULAR THERAPIES, INC., THE ROCKEFELLER UNIVERSITYInventors: Paul Greengard, Wenjie Luo, Gen He, Peng Li, Lawrence Wennogle
-
Patent number: 9598426Abstract: Provided are PDE1 inhibitors of Formula I, processes for their production and their use as pharmaceuticals, and pharmaceutical compositions comprising them.Type: GrantFiled: March 13, 2014Date of Patent: March 21, 2017Assignee: INTRA-CELLULAR THERAPIES, INC.Inventors: Peng Li, Hailin Zheng, Jun Zhao, Lawrence Wennogle
-
Patent number: 9545406Abstract: The subject matter generally relates to methods of treatment and/or prophylaxis of CNS diseases, disorders, and/or injuries. In one aspect, the subject matter relates to inhibitors of phosphodiesterase 1 (PDE1) as neuroprotective agents and/or neural regenerative agents. In a further aspect, the subject matter relates to individuals that are at risk for the development of CNS disease or disorder.Type: GrantFiled: March 17, 2014Date of Patent: January 17, 2017Assignee: INTRA-CELLULAR THERAPIES, INC.Inventor: Lawrence Wennogle
-
Patent number: 9428506Abstract: The invention relates to particular substituted heterocycle fused gamma-carbolines, of Formula I, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) and/or pathways involving dopamine D2 receptor signaling systems, such as disease of the central nervous system.Type: GrantFiled: April 14, 2013Date of Patent: August 30, 2016Assignee: INTRA-CELLULAR THERAPIES, INC.Inventors: Sharon Mates, Robert Davis, Peng Li, Lawrence Wennogle, Kimberly Vanover
-
Publication number: 20150080404Abstract: The present invention relates to use of particular substituted heterocycle fused gamma-carbolines as described herein, in free, pharmaceutically acceptable salt or prodrug form, and pharmaceutical composition comprising the same optionally in combination with one or more agents, for the prophylaxis or treatment of one or more disorders associated with dementia, particularly behavioral or mood disturbances (e.g., agitation/aggression), psychosis, depression and sleep disturbances among others in patients suffering from dementia.Type: ApplicationFiled: April 14, 2013Publication date: March 19, 2015Inventors: Sharon Mates, Robert Davis, Kimberly Vanover, Lawrence Wennogle
-
Publication number: 20150079172Abstract: The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) and/or pathways involving dopamine D2 receptor signaling systems.Type: ApplicationFiled: April 14, 2013Publication date: March 19, 2015Inventors: Sharon Mates, Robert Davis, Peng Li, Lawrence Wennogle, Richard A. Lerner
-
Publication number: 20150072964Abstract: Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals for the treatment of agitation, aggressive behaviors, posttraumatic stress disorder or impulse control disorders.Type: ApplicationFiled: April 14, 2013Publication date: March 12, 2015Inventors: Sharon Mates, Robert Davis, Kimberly Vanover, Lawrence Wennogle
-
Patent number: 8697710Abstract: The present invention relates to optionally substituted 3-amino-4,5-dihydro-(1H or 2H)-pyrazolo[3,4-d]pyrimidin-6(7H)-ones and their 4-imino or 4-thioxo derivatives, e.g., 3-amino-4-(thioxo or imino)-4,5-dihydro-2H-pyrazolo[3,4-d]pyrimidin-6(7H)-ones, 3-amino-4-(thioxo or imino)-4,5-dihydro-2H-pyrazolo[3,4-d]pyrimidin-6(7H)-ones, 3-amino-4-(thioxo or imino)-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-6(7H)-ones, processes for their production, their use as pharmaceuticals and pharmaceutical compositions comprising them.Type: GrantFiled: December 7, 2009Date of Patent: April 15, 2014Assignee: Intra-Cellular Therapies, Inc.Inventors: Peng Li, Jun Zhao, Hailin Zeng, Lawrence Wennogle
-
Patent number: 8664207Abstract: Optionally substituted 4,5,7,8-tetrahydro-(optionally 4-oxo, 4-thioxo or 4-imino)-2H-imidazo[1,2-a]pyrrolo[3,4-e]pyrimidine or 4,5,7,8,9-pentahydro-(optionally 4-oxo, 4-thioxo or 4-imino)-2H-pyrimido[1,2-a]pyrrolo[3,4-e]pyrimidine compounds or Compounds of Formula (I), processes for their production, their use as pharmaceuticals and pharmaceutical compositions comprising the same.Type: GrantFiled: December 7, 2009Date of Patent: March 4, 2014Assignee: Intra-Cellular Therapies, Inc.Inventors: Peng Li, Jun Zhao, Hailin Zheng, Lawrence Wennogle
-
Patent number: 8633180Abstract: Optionally substituted 4,5,7,8-tetrahydro-(optionally 4-thioxo or 4-imino)-(1H or 2H)-imidazo[1,2-a]pyrazolo[4,3-e]pyrimidine or 4,5,7,8,9-pentahydro-(optionally 4-thioxo or 4-imino)-(1H or 2H)-pyrimido[1,2-a]pyrazolo[4,3-e]pyrimidine compounds or Compounds of Formula (I), processes for their production, their use as pharmaceuticals and pharmaceutical compositions comprising them.Type: GrantFiled: December 7, 2009Date of Patent: January 21, 2014Assignee: Intra-Cellular Therapies, Inc.Inventors: Peng Li, Jun Zhao, Hailin Zeng, Lawrence Wennogle
-
Patent number: 8598119Abstract: Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals and pharmaceutical compositions comprising them for the treatment of one or more disorders involving the 5-HT2A, SERT and/or dopamine D2 pathways are disclosed. In addition, the compounds may be combined with other therapeutic agents for the treatment of one or more sleep disorders, depression, psychosis, dyskinesias, and/or Parkinson's disease or any combinations.Type: GrantFiled: May 27, 2009Date of Patent: December 3, 2013Assignee: Intra-Cellular Therapies, Inc.Inventors: Sharon Mates, Allen Fienberg, Lawrence Wennogle
-
Patent number: 8536159Abstract: Optionally substituted 3-(thio, sulfonyl or sulfonyl)-7,8-dihydro-(1H or 2H)-imidazo[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5H)-one or a substituted 3-(thio, sulfinyl or sulfonyl)-7,8,9-trihydro-(1H or 2H)-pyrimido[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5H)-one compounds or Compounds of Formula (I), processes for their production, their use as pharmaceuticals and pharmaceutical compositions comprising them.Type: GrantFiled: December 7, 2009Date of Patent: September 17, 2013Assignee: Intra-Cellular Therapies, Inc.Inventors: Peng Li, Jun Zhao, Hailin Zeng, Lawrence Wennogle
-
Publication number: 20120094966Abstract: The present invention relates to optionally substituted 3-amino-4,5-dihydro-(1H or 2H)-pyrazolo[3,4-d]pyrimidin-6(7H)-ones and their 4-imino or 4-thioxo derivatives, e.g., 3-amino-4-(thioxo or imino)-4,5-dihydro-2H-pyrazolo[3,4-d]pyrimidin-6(7H)-ones, 3-amino-4-(thioxo or imino)-4,5-dihydro-2H-pyrazolo[3,4-d]pyrimidin-6(7H)-ones, 3-amino-4-(thioxo or imino)-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-6(7H)-ones, processes for their production, their use as pharmaceuticals and pharmaceutical compositions comprising them.Type: ApplicationFiled: December 7, 2009Publication date: April 19, 2012Inventors: Peng Li, Jun Zhao, Hailin Zheng, Lawrence Wennogle
-
Patent number: RE48839Abstract: Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals and pharmaceutical compositions comprising them for the treatment of one or more disorders involving the 5-HT2A, SERT and/or dopamine D2 pathways are disclosed. In addition, the compounds may be combined with other therapeutic agents for the treatment of one or more sleep disorders, depression, psychosis, dyskinesias, and/or Parkinson's disease or any combinations.Type: GrantFiled: February 6, 2020Date of Patent: December 7, 2021Assignee: Intra-Cellular Therapies, IncInventors: Sharon Mates, Allen Fienberg, Lawrence Wennogle